Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma

Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe side effects than other agents used for that purpose. However, due to a lack of tumor-specific targeting, the concentration of the drug in tumor tissue cannot be permanently maintained at a level that i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Deliv
Hlavní autoři: Tang, Xiaolong, Chen, Longzhou, Li, Amin, Cai, Shiyu, Zhang, Yinci, Liu, Xueke, Jiang, Zhenyou, Liu, Xinkuang, Liang, Yong, Ma, Dong
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058710/
https://ncbi.nlm.nih.gov/pubmed/29916268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10717544.2018.1477859
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky